DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

DIGITAL CONTENT

15 NEWS #PharmaBuzz

media
15 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1426698-88-5, Incb050465, Parsaclisib [inn], Parsaclisib [usan], Incb-050465, Os7097575k

Molecular Formula

C₂₀H₂₂ClFN₆O₂

Molecular Weight

432.9 g/mol

InChI Key

ZQPDJCIXJHUERQ-QWRGUYRKSA-N

FDA UNII

OS7097575K

Parsaclisib is an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.

1 2D Structure

Parsaclisib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one

2.1.2 InChI

InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1

2.1.3 InChI Key

ZQPDJCIXJHUERQ-QWRGUYRKSA-N

2.1.4 Canonical SMILES

CCOC1=C(C(=C(C=C1C(C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)C4CC(=O)NC4

2.1.5 Isomeric SMILES

CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4

2.2 Other Identifiers

2.2.1 UNII

OS7097575K

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

2. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

3. Incb050465

2.3.2 Depositor-Supplied Synonyms

1. 1426698-88-5

2. Incb050465

3. Parsaclisib [inn]

4. Parsaclisib [usan]

5. Incb-050465

6. Os7097575k

7. (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one

8. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

9. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

10. Parsaclisib (usan/inn)

11. Parsaclisib [usan:inn]

12. Incb050465 Free Base

13. Parsaclisib [who-dd]

14. Incb-050465 Free Base

15. Parsaclisib (incb050465)

16. Chembl4297615

17. Schembl14736228

18. Unii-os7097575k

19. Bdbm272573

20. Ex-a2638

21. Who 10589

22. Db14867

23. Ac-36916

24. Us10065963, 32c

25. Hy-109068

26. Cs-0033435

27. D11437

28. (r)-4-(3-((s)-1-(4-amino-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

2.4 Create Date

2015-02-02

3 Chemical and Physical Properties

Molecular Formula	C₂₀H₂₂ClFN₆O₂
Molecular Weight	432.9 g/mol
XLogP3	2.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	5
Exact Mass	432.1476798 g/mol
Monoisotopic Mass	432.1476798 g/mol
Topological Polar Surface Area	108 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	632
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of mature B-cell malignancies

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Parsaclisib manufacturers, exporters & distributors on PharmaCompass

Parsaclisib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DEVELOPMENTS

7 Drugs in Development

DIGITAL CONTENT

15 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

7DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?